SARS-COV2 breakthrough infection in health personnel of the Hospital Escuela Hospital with complete vaccination.

Hospital Escuela began its vaccination campaign for COVID-19 in February 2021, with an initial  goal of vaccinating 4,198 employees that included permanent staff, interns, and other collaborators. Vaccination strategy included in house and external nurses from the national health ministry our purpose was initially immunizing front-line personnel but we extended to all personnel working at the hospital. 

We carried out a cross-sectional observational study, using an electronic form, filled out personally by the employees from September 7 to 25. The data was recorded using an Excel spreadsheet, classifying the information for subsequent descriptive statistical analysis. Findings: 91.51% (3842) of the employees were vaccinated, 8.4% (356) of the staff whose vaccination status is unknown. Of those vaccinated, 85.94% (3266) received the ChAdOx1 Ncov-19 AstraZeneca vaccine, 10.90% (419) mRNA-1273 Moderna, 2.55% (98) Sputnik V vaccine, 1.48% (57) BNT162b2 from Pfizer, and 0.02 % (2) with the Johnson and Johnson and Sinovac vaccine. 

Of the 3,842 employees with a complete vaccination schedule, 3.7% (142) were diagnosed by Real-Time Polymerase Chain Reaction (PCR-RT) or Rapid Diagnostic Antigen Detection Test (Ag-RDT) fourteen days or more after vaccination. application of the second dose of the vaccine. 98.6% (142) of those infected presented mild symptoms and 1.4% (2) presented pneumonia requiring supplemental oxygen. No deaths reported. Of the infected vaccinated personnel, 3.2% (126/3842) were vaccinated with AstraZeneca, 0.28% (11/3842) with Moderna, 0.10% (4/3842) with Sputnik V, and 0.02% (1/3842) with Pfizer. . 

Of the personnel with a complete vaccination schedule diagnosed with Covid-19, most had received the Astrazeneca vaccine, however, a comparison of the effectiveness of the vaccines cannot be made, because the sample of those immunized with the other vaccines it is very less.